Which drug combination for hormone-refractory prostate cancer?

Area of Science:

• Oncology
• Clinical Trials
• Prostate Cancer Research

Background:

• Metastatic hormone-refractory prostate cancer (mHRPC) presents a significant clinical challenge with limited treatment options and poor prognosis.
• Current standard care often involves corticosteroids and chemotherapy, such as mitoxantrone, but lacks definitive survival advantages.

Purpose of the Study:

• To evaluate the efficacy and safety of docetaxel-based regimens compared to mitoxantrone/prednisone in patients with mHRPC.
• To assess the impact of these treatments on survival, pain, prostate-specific antigen (PSA) levels, and quality of life.

Main Methods:

• Two clinical trials are presented comparing docetaxel/prednisone versus mitoxantrone/prednisone, and docetaxel/estramustine versus mitoxantrone/prednisone.
• Patient outcomes including mortality, median survival, pain reduction, PSA levels, and quality of life were analyzed.

Main Results:

• Docetaxel/prednisone demonstrated fewer deaths and longer median survival (18.9 months) compared to mitoxantrone/prednisone (16.5 months).
• Docetaxel/estramustine also showed improved survival outcomes (17.5 months) versus mitoxantrone/prednisone (15.6 months).
• Docetaxel-based treatments reduced pain, lowered PSA levels, and improved quality of life compared to the control group.

Conclusions:

• Both docetaxel/prednisone and docetaxel/estramustine regimens are superior to mitoxantrone/prednisone for treating hormone-refractory prostate cancer.
• These docetaxel combinations represent valuable therapeutic options for patients with advanced prostate cancer.
• Further comparative studies may be needed to definitively distinguish between the two docetaxel combinations.